Key result
Rivaroxaban treatment for 6 months in patients with active cancer and acute venous thromboembolism resulted in a cumulative incidence of symptomatic recurrent VTE of 5.9%.
Why the study?
Does oral rivaroxaban prevent symptomatic recurrent VTE in patients with active cancer and acute VTE?
Does oral rivaroxaban prevent symptomatic recurrent VTE in patients with active cancer and acute VTE?
Long-term rivaroxaban is an effective and safe alternative for treating cancer-associated venous thromboembolism, demonstrating low rates of symptomatic recurrence.
No takes yet. Share an insight, caveat, or question.
Supports rivaroxaban in cancer-associated VTE; leaves open need for randomized trials versus LMWH.
Yhim et al. (2018) studied Acute venous thromboembolism in patients with active cancer (n=124). Rivaroxaban was evaluated on Symptomatic recurrent VTE during the 6-month period (95% CI 2.6-11.1). Rivaroxaban treatment for 6 months in patients with active cancer and acute venous thromboembolism resulted in a cumulative incidence of symptomatic recurrent VTE of 5.9%.